Englander Institute for Precision Medicine
Found 797 results
Author Title Type [ Year(Desc)]
Filters: Clinical-trials-corner-issue-10(1) is   [Clear All Filters]
2024
Klomp JE, J Diehl N, Klomp JA, A Edwards C, Yang R, Morales AJ, Taylor KE, Drizyte-Miller K, Bryant KL, Schaefer A et al..  2024.  Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancer.. Science. 384(6700):eadk0850.
Greenberg JA, Shah Y, Ivanov NA, Marshall T, Kulm S, Williams J, Tran C, Scognamiglio T, Heymann JJ, Lee-Saxton YJoo et al..  2024.  Developing a predictive model for metastatic potential in pancreatic neuroendocrine tumor.. J Clin Endocrinol Metab.
Forbes ANeil, Xu D, Cohen S, Pancholi P, Khurana E.  2024.  Discovery of therapeutic targets in cancer using chromatin accessibility and transcriptomic data.. Cell Syst.
McIntyre CA, Grimont A, Park J, Meng Y, Sisso WJ, Seier K, Jang GHo, Walch H, Aveson VG, Falvo DJ et al..  2024.  Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer.. Cancer Cell. 42(9):1614-1629.e5.
Risnik D, Colado A, Podaza E.  2024.  Editorial: Myeloid cell reprogramming: molecular pathways involved in disease development.. Front Immunol. 15:1414482.
Shore ND, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford D, Tombal B, Nordquist L, Cookson M, Verholen F et al..  2024.  Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Black Patients From the Randomized ARASENS Trial.. Oncologist. 29(3):235-243.
Windon A, Assaad MAl, Hadi K, Mendelson N, Hissong E, Deshpande A, Tranquille M, Mclee J, Levine MF, Patel M et al..  2024.  Emerging molecular phenotypes and potential therapeutic targets in esophageal and gastric adenocarcinoma unearthed by whole genome and transcriptome analyses.. Pathol Res Pract. 266:155788.
Assaad MAl, Hadi K, Tu J, Levine MF, Patel M, Deshpande A, Manohar J, Sigouros M, Sboner A, Chapman-Davis E et al..  2024.  Enhancing the detection of clinically relevant biomarkers in advanced uterine and tubo-ovarian carcinomas through genome-wide analysis.. Pathol Res Pract. 266:155773.
Cicin I, Plimack ER, Gurney H, Leibowitz R, Alekseev BY, Parnis FX, Peer A, Necchi A, Bellmunt J, Nishiyama H et al..  2024.  Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study.. BMC Cancer. 23(Suppl 1):1256.
Mack TM, Raddatz MA, Pershad Y, Nachun DC, Taylor KD, Guo X, Shuldiner AR, O'Connell JR, Kenny EE, Loos RJF et al..  2024.  Epigenetic and proteomic signatures associate with clonal hematopoiesis expansion rate.. Nat Aging.
Galassi C, Esteller M, Vitale I, Galluzzi L.  2024.  Epigenetic control of immunoevasion in cancer stem cells.. Trends Cancer.
Spada S, Galluzzi L.  2024.  Epigenetic regulation of cancer.. Int Rev Cell Mol Biol. 383:xi-xv.
Spada S, Galluzzi L.  2024.  Epigenetic regulation of cancer.. Int Rev Cell Mol Biol. 387:xiii-xvii.
Stenzl A, Armstrong AJ, Rogers E, Habr D, Walz J, Gleave M, Sboner A, Ghith J, Serfass L, Schuler KW et al..  2024.  Evaluation of ChatGPT as a Reliable Source of Medical Information on Prostate Cancer for Patients: Global Comparative Survey of Medical Oncologists and Urologists.. Urol Pract. :101097UPJ0000000000000740.
Ohara K, Rendeiro AFigueiredo, Bhinder B, Eng KWha, Ravichandran H, Nguyen D, Pisapia D, Vosoughi A, Fernandez E, Shohdy KS et al..  2024.  The evolution of metastatic upper tract urothelial carcinoma through genomic-transcriptomic and single-cell protein markers analysis.. Nat Commun. 15(1):2009.
Sternberg CN, Loriot Y, Choy E, Castellano D, Lopez-Rios F, Banna GLuigi, Zengerling F, De Giorgi U, Gedye C, Masini C et al..  2024.  Final Results from SAUL, a Single-arm International Study of Atezolizumab in Unselected Patients with Pretreated Locally Advanced/Metastatic Urinary Tract Carcinoma.. Eur Urol Focus.
Campia G, Beltrán-Visiedo M, Soler-Agesta R, Sato A, Bloy N, Zhao L, Liu P, Kepp O, Kroemer G, Galluzzi L et al..  2024.  Flow cytometry-assisted analysis of phenotypic maturation markers on an immortalized dendritic cell line.. Methods Cell Biol. 189:153-168.
Soler-Agesta R, Ripollés-Yuba C, Marco-Brualla J, Moreno-Loshuertos R, Sato A, Beltrán-Visiedo M, Galluzzi L, Anel A.  2024.  Generation of transmitochondrial cybrids in cancer cells.. Methods Cell Biol. 189:23-40.
Suhre K.  2024.  Genetic associations with ratios between protein levels detect new pQTLs and reveal protein-protein interactions.. Cell Genom. 4(3):100506.
Suhre K, Chen Q, Halama A, Mendez K, Dahlin A, Stephan N, Thareja G, Sarwath H, Guturu H, Dwaraka VB et al..  2024.  A genome-wide association study of mass spectrometry proteomics using the Seer Proteograph platform.. bioRxiv.
Dai E, Chen X, Linkermann A, Jiang X, Kang R, Kagan VE, Bayir H, Yang WSeok, Garcia-Saez AJ, Ioannou MS et al..  2024.  A guideline on the molecular ecosystem regulating ferroptosis.. Nat Cell Biol.
Sanidad KZ, Rager SL, Carrow HC, Ananthanarayanan A, Callaghan R, Hart LR, Li T, Ravisankar P, Brown JA, Amir M et al..  2024.  Gut bacteria-derived serotonin promotes immune tolerance in early life.. Sci Immunol. 9(93):eadj4775.
Galassi C, Chan TA, Vitale I, Galluzzi L.  2024.  The hallmarks of cancer immune evasion.. Cancer Cell. 42(11):1825-1863.
Annabestani M, Sriram S, Caprio A, Janghorbani S, S Wong C, Sigaras A, Mosadegh B.  2024.  High-fidelity pose estimation for real-time extended reality (XR) visualization for cardiac catheterization.. Sci Rep. 14(1):26962.
Ranti D, Yu H, Wang YA, Bieber C, Strandgaard T, Salomé B, Houghton S, Kim J, Ravichandran H, Okulate I et al..  2024.  HLA-E and NKG2A Mediate Resistance to M. bovis BCG Immunotherapy in Non-Muscle-Invasive Bladder Cancer.. bioRxiv.